IN BRIEF: Oncimmune shares dive; laments slow conversion of contracts

Oncimmune Holdings PLC - Leeds, England-based autoantibody profiling research services to ...

Alliance News 31 January, 2025 | 9:58AM
Email Form Facebook Twitter LinkedIn RSS

Oncimmune Holdings PLC - Leeds, England-based autoantibody profiling research services to pharmaceutical and biotechnology industry to enable delivery of precision medicine - Reiterates it expects to report revenue of around GBP3 million for the financial year ended August 31, surged from GBP1.2 million a year prior. However, notes that since the end of October, one potential contract was deferred into financial year 2026, and one was removed from its pipeline.

For financial 2025, the firm expects revenue of around GBP4 million, up 33% from financial 2024.

"In line with the rest of the Pharma services outsourcing market, conversion of new contracts has been slower than since late 2024. At the same time as vigorously pursuing follow-on work, Oncimmune is discussing a number of significant strategic collaborations and transformative contracts with several parties which, whilst there is no certainty, could materially improve its revenue position in FY2025," the company says.

Current stock price: 9.90 pence each, down 20% on Friday morning in London

12-month change: down 61%

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Oncimmune Holdings PLC 9.90 GBX -20.48 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures